^
    Back
    Association details:
    Biomarker:BRAF mutation + TP53 mutation
    Cancer:Pancreatic Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Case Rep Oncol
    Title:

    Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy

    Published date:
    10/13/2020
    Excerpt:
    She was found to have both a BRAF and P53 mutation, and received dabrafenib and trametinib with deep responses, both radiographically and biochemically (CA19-9)...To the best of our knowledge, this is the first case report showing a dramatic therapeutic response to combination therapy with dabrafenib and trametinib in metastatic pancreatic cancer.
    DOI:
    10.1159/000510096